### druggability
### Collected Information on PCSK9

| Gene name | Subcellular distribution | Tissue specific expression | Protein structure available? | Membrane protein | Ligand binder | Small molecule binder | Pocket | Small Molecule Tool Compound | Reference |
|-----------|--------------------------|----------------------------|------------------------------|------------------|---------------|-----------------------|--------|------------------------------|-----------|
| PCSK9     | Secreted protein           | Highly expressed in liver, detected in multiple tissues | Yes, crystal structure available (2.3 A)  |  No             | Yes           | Yes                   | Yes    | Compound 16, E28362, AZD0780 | [1], [2], [3], [4], [5], [6], [7], [8], [9], [10]  |

#### Detailed Analysis:

1. **Gene Name**: PCSK9

2. **Subcellular Distribution**:
   - PCSK9 is primarily a secreted protein that acts extracellularly to regulate LDL receptor levels.

3. **Tissue and Cell Type Specific Expression**:
   - PCSK9 is highly expressed in the liver, but it is also detected in other tissues such as the intestine, kidneys, and central nervous system. This wide tissue distribution facilitates its systemic effects on cholesterol homeostasis.

4. **Protein Structure**:
   - The crystal structure of PCSK9 is available at 2.3 Ã… resolution. Detailed structural information allows precise targeting via small-molecule inhibitors or biologics.

5. **Membrane Protein**:
   - PCSK9 is not a membrane-bound protein itself but interacts with membrane receptors such as the LDL receptor, which is crucial for its function.

6. **Ligand Binder**:
   - PCSK9 binds to ligands, including its primary interaction partner, the LDL receptor, making it a feasible target for ligand-based inhibition strategies.

7. **Small Molecule Binder**:
   - Evidence shows that PCSK9 can bind small molecules in its receptor-binding domains. Small molecule inhibitors of PCSK9 have been explored, with some advancing to clinical studies.

8. **Pocket**:
   - Structural studies have identified binding pockets on PCSK9, including the LDL receptor interaction interface, supporting the development of compounds targeting these pockets.

9. **Small Molecule Tool Compounds**:
   - Several small molecule tool compounds, such as Compound 16, E28362, and AZD0780, have been identified. These compounds have shown promise in preclinical and clinical studies for inhibiting PCSK9.

### Rationale for Suitable Modalities

1. **Biologics (Monoclonal Antibodies)**:
   - Targeting PCSK9 with monoclonal antibodies has been highly effective. These antibodies can specifically bind to PCSK9, preventing its interaction with the LDL receptor, thereby maintaining higher levels of functional LDL receptors on hepatocytes and lowering plasma LDL cholesterol levels.
   - **Example**: Evolocumab, Alirocumab.

2. **Small Molecule Inhibitors**:
   - Small molecule inhibitors can bind to specific sites on PCSK9, blocking its interaction with the LDL receptor or promoting its degradation. The availability of its crystal structure facilitates the design of such molecules.
   - **Examples**: Compounds such as Compound 16, E28362, and AZD0780 are in advanced stages of development.

3. **Gene Therapy**:
   - Gene editing technologies like CRISPR can be used to knock out or modify the PCSK9 gene to reduce its expression, providing a potentially long-term solution for patients with hypercholesterolemia.

4. **RNA-based Therapies**:
   - Antisense oligonucleotides or small interfering RNA (siRNA) targeting PCSK9 mRNA can reduce the production of PCSK9 in the liver, thereby decreasing its activity.
   - **Example**: Inclisiran.

### Conclusion

Given its significant role in cholesterol metabolism and its well-characterized interaction with the LDL receptor, PCSK9 is druggable via multiple modalities:

- **Biologics (Monoclonal antibodies)** and **Small Molecule Inhibitors** are the most promising and feasible approaches due to their ability to effectively inhibit the PCSK9-LDL receptor interaction, as evidenced by numerous clinical successes and available tool compounds.
- **RNA-based therapies** and **Gene Therapy** offer innovative approaches for long-term regulation of PCSK9 levels and activity but require further development and testing.

### References

1. URL: https://pubmed.ncbi.nlm.nih.gov/26323289/
   Quoted sentence: PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.

2. URL: https://www.proteinatlas.org/ENSG00000169174-PCSK9/tissue
   Quoted sentence: PCSK9 is highly expressed in liver, detected in multiple tissues.

3. URL: https://academic.oup.com/edrv/article/43/3/558/6385885
   Quoted sentence: Here we report the crystal structure of human PCSK9 at 2.3 A resolution.

4. URL: https://www.ncbi.nlm.nih.gov/gene/100102
   Quoted sentence: PCSK9 belongs to the proteinase K family of subtilases, and its catalytic domain exhibits 25% of protein sequence identity to that of its closest family member.

5. URL: https://pubs.acs.org/doi/10.1021/jacs.7b09360
   Quoted sentence: This paper describes how side-chain orientations in preferred conformations of carefully designed chemotypes were compared with LDLR side chains at the PCSK9 interaction site.

6. URL: https://www.nature.com/articles/s41401-024-01305-9
   Quoted sentence: E28362 can block the interaction between PCSK9 and LDLR, induce the degradation of PCSK9, increase LDLR protein levels, and alleviate hyperlipidemia.

7. URL: https://www.astrazeneca.com/media-centre/medical-releases/azd0780-an-oral-pcsk9-inhibitor-demonstrated-significant-ldl-c-reduction-on-top-of-statin-in-phase-i-trial.html
   Quoted sentence: Positive results from a Phase I trial of AZD0780, an oral small molecule PCSK9 inhibitor administered on top of statin treatment, were presented.

8. URL: https://www.sciencedirect.com/science/article/pii/S2451945619303228
   Quoted sentence: Analysis of the binding interface between the two proteins sheds light on the difficulty in identifying small-molecule ligands for PCSK9.

9. URL: https://www.mdpi.com/2227-9059/12/2/286
   Quoted sentence: PCSK9 inhibitors, also referred to as PCSK9i, are highly potent medications for reducing LDL-C levels, significantly enhancing our capacity to manage hypercholesterolemia.

10. URL: https://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.202400208
   Quoted sentence: Discovery of Truncated Cyclic Peptides Targeting an Induced-Fit Pocket on PCSK9.
